Listen: CRISPR history, biotech struggles, & a big week for deals
This week on "The Readout LOUD" podcast: How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million?
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atlas Venture joins us to discuss what was yet another downbeat year for biotech and whether there’s reason for optimism heading into 2024.
What's Your Reaction?
